Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma

Japanese Journal of Cancer Research

Volumn 91, Issue 4, 2000, Pages 410-415

  Kanke, Minoru ^a   Fujii, Masato ^a   Kameyama, Kaori ^a   Kanzaki, Jin ^a   Tokumaru, Yutaka ^a   Imanishi, Yorihisa ^a   Tomita, Toshiki ^a   Matsumura, Yasuhiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Biological marker; CD44 variant; Head and neck squamous cell carcinoma; Immunohistochemistry; Prognostic factor

Indexed keywords

BIOLOGICAL MARKER; CD44V ANTIGEN; CELL SURFACE PROTEIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL; TUMOR GROWTH;

EID: 0034025973     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00960.x     Document Type: Article

References (31)

1. Haynes, B. F., Telen, M. J., Hale, L. P. and Denning, S. M. CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol. Today, 10, 423-428 (1989).
2. Streit, M., Schmidt, R., Hilgenfeld, R. U., Thiel, E. and Kreuser, E. D. Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors, Recent Results Cancer Res., 142, 19-50 (1996).
3. Jalkanen, S., Bargatze, R. F., de los Toyos, J. and Butcher, E. C. Lymphocyte recognition of high endothelium: anti-bodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol., 105, 983-990 (1987).
4. Arch, R., Wirth, K., Hofmann, M., Ponta, H., Matzku, S., Herrlich, P. and Zöller, M. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science, 257, 682-685 (1992).
5. Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haußmann, I., Matzku, S., Wenzel, A., Ponta, H. and Herrlich, P. A new variant glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24 (1991).
6. Mutsumura, Y. Hanbury, D., Smith, J. and Tarin, D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. Br. Med. J., 308, 619-624 (1994).
7. Matsumura, Y., Sugiyama, M., Matsumura, S., Hayle, A. J., Robinson, P., Smith, J. C. and Tarin, D. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J. Pathol., 177, 11-20 (19951).
8. Matsumura, Y. and Tarin, D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340, 1053-1058 (1992).
9. Herrlich, P., Zoller, M., Pals, S. T. and Ponta, H. CD44 splice variants: metastases meet lymphocytes. Immunol. Today, 14, 395-399 (1993).
10. Mayer, B., Jauch, K. W., Günthert, U., Figdor, C. G., Schildberg, F. W., Funke, I. and Johnson, J. P. De-novo expression of CD44 and survival in gastric cancer. Lancet, 342, 1019-1022 (1993).
11. Mulder, J. W., Kruyt, P. M., Sewnath, M., Oosting, J., Seldenrijk, C. A., Weidema, W. F., Ofterhaus, G. J. and Pals, S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 344, 1470-1472 (1994).
12. Yamaguchi, A., Urano, T., Goi, T., Saito, M., Takeuchi, K., Hirose, K., Nakagawara, G., Shiku, H and Furukawa, K. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients, J. Clin. Oncol., 14, 1122-1127 (1996).
13. Kaufmann, M., Heider, K. H., Sinn, H. P., von Minckwitz, G., Ponta, H. and Herrlich, P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345, 615-619 (1995).
14. Stauder, R., Eisterer, W., Thaler, J. and Günthert, U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood, 83, 2885-2899 (1995).
15. Tokue, Y., Matsumura, Y., Katsumata, N., Watanabe, T., Tarin, D. and Kakizoe, T. CD44 variant isoform expression and breast cancer prognosis. Jpn. J. Cancer Res., 89, 283-290 (1998).
16. Gotoda, T., Matsumura, Y., Kondo, H., Saitoh, D., Shimada, Y., Kosuge, T., Kanai, Y. and Kakizoe, T. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn. J. Cancer Res., 89, 1033-1040 (1998).
17. Favrot, M. C., Combaret, V. and Lasset, C. CD44 -a new prognostic marker for neuroblastoma, N. Engl. J. Med., 329, 1965 (1993).
18. Spafford, M. F., Koeppe, J., Pan, Z., Archer, P. G., Meyers, A. D. and Franklin, W. A. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 122, 627-632 (1996).
19. Gotoda, T., Matsumura, Y., Kondo, H., Ono, H., Kanamoto, A., Kato, H., Watanabe, H., Tachimori, Y., Nakanishi, Y. and Kakizoe, T. Expression of CD44 variants and prognosis in esophageal squamous cell carcinoma. Gut. 46, 9-14 (2000).
20. Borgya, A., Woodman, A. C., Sugiyama, M., Donie, F., Kopetzki, E., Matsumura, Y. and Tarin, D. Isolation and characterisation of antibodies which specifically recognise the peptide encoded by exon 7 (v2) of the human CD44 gene. J. Clin. Pathol. Mol. Pathol., 48, M241-250 (1995).
21. Kaplan, E. L. and Meier, P. Non parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53, 457-481 (1958).
22. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34, 187-220 (1972).
23. Soukka, T., Salmi, M., Joensuu, H., Hakkinen, L., Sointu, P., Koulu, L., Kalimo, K., Klemi, P., Grenman, R. and Jalkanen, S. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res., 57, 2281-2289 (1997).
24. Bahar, R., Kunishi. M., Kayada, Y. and Yoshiga, K. CD44 variant 6 (CD44v6) expression as a progression marker in benign, premalignant and malignant oral epithelial tissues. Int. J. Oral Maxillofac. Surg., 26, 443-446 (1997).
25. Kunishi, M., Kayada, Y. and Yoshiga, K. Down-regulated expression of CD44 variant 6 in oral squamous cell carcinomas and its relationship to regional lymph node metastasis. Int. J. Oral Maxillofac. Surg., 26, 280-283 (1997).
26. Heider, K. H., Sproll, M., Susani, S., Patzelt, E., Beaumier, P., Ostermann, E., Ahorn, H. and Adolf, G. R. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother., 43, 245-253 (1996).
27. Herold-Mende, C., Seiter, S., Born, A. I., Patzelt, E., Schupp. M., Zöller, J., Bosch, F. X. and Zöller, M. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J. Pathol., 179, 66-73 (1996).
28. Fujita, N., Yaegashi, N,. Ide, Y., Sato, S., Nakamura, M., Ishiwata, I. and Yajima, A. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res., 54, 3922-3928 (1994).
29. Bourguignon, L. Y., Gunja-Smith, Z., Iida, N., Zhu, H. B., Young, E. J., Muller, W. J. and Cardiff, R. D. CD44v3.8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell Physiol., 176, 206-215 (1998).
30. Okamoto, I., Kawano, Y., Tsuiki, H., Sasaki, J., Nakao, M., Matsumoto, M., Suga, M., Ando, M., Nakajima, M. and Saya, H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene, 18, 1435-1446 (1999).
31. Takahashi, K., Eto, H. and Tanabe, K. K. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int. J. Cancer, 80, 387-395 (1999).